Ordering Recommendation

Monitor patient adherence.

Mnemonic

OPIS SP

Methodology

Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Mon, Wed, Fri

Reported

1-4 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).

Specimen Preparation

Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens.

Remarks
Stability

After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years

Reference Interval

Effective August 17, 2015

Drugs Covered Cutoff Concentrations
Codeine 2 ng/mL
Morphine 2 ng/mL
6-acetylmorphine 2 ng/mL
Hydrocodone 2 ng/mL
Hydromorphone 2 ng/mL
Oxycodone 2 ng/mL
Oxymorphone 2 ng/mL

Interpretive Data

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff: 2 ng/mL

For medical purposes only; not valid for forensic use.

Identification of specific drug(s) taken by specimen donor is problematic due to common metabolites, some of which are prescriptions drugs themselves. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. All drugs covered are the non-glucuronidated (free) form. The concentration value must be greater than or equal to the cutoff to be reported as positive. A very small amount of an unexpected drug analyte in the presence of a large amount of an expected drug analyte may reflect pharmaceutical impurity. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

80361; 80365 (Alt code: G0480)

Components

Component Test Code* Component Chart Name LOINC
2006559 Hydrocodone, S/P, Quant 3680-6
2006560 Hydromorphone, S/P, Quant 3683-0
2006561 Codeine, S/P, Quant 3506-3
2006562 Morphine, S/P, Quant 3827-3
2006563 6-acetylmorphine, S/P, Quant 12788-6
2006564 Oxycodone, S/P, Quant 3893-5
2006565 Oxymorphone, S/P, Quant 60467-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Codeine
  • Codeine and Metabolite
  • Dilaudid
  • Heroin
  • Hydrocodone and Metabolite
  • Hydromorphone
  • Morphine
  • MS Contin
  • Norco
  • Opana
  • Opiates Quantitation
  • Oxycodone
  • Oxycodone and Metabolite
  • OxyContin
  • Oxymorphone
  • Pain Management
  • Percocet
  • Percodan
  • Roxicet
  • Roxiprin
  • Tylox
Opiates, Serum or Plasma, Quantitative